X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs GLENMARK PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA GLENMARK PHARMA ABBOTT INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 32.3 13.5 239.4% View Chart
P/BV x 8.1 3.8 213.5% View Chart
Dividend Yield % 0.8 0.3 247.6%  

Financials

 ABBOTT INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
GLENMARK PHARMA
Mar-16
ABBOTT INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs6,0151,262 476.6%   
Low Rs3,707672 552.0%   
Sales per share (Unadj.) Rs1,236.9270.6 457.2%  
Earnings per share (Unadj.) Rs122.224.9 491.1%  
Cash flow per share (Unadj.) Rs129.034.4 374.8%  
Dividends per share (Unadj.) Rs35.002.00 1,750.0%  
Dividend yield (eoy) %0.70.2 348.0%  
Book value per share (Unadj.) Rs521.2151.3 344.4%  
Shares outstanding (eoy) m21.25282.16 7.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.93.6 110.0%   
Avg P/E ratio x39.838.9 102.4%  
P/CF ratio (eoy) x37.728.1 134.2%  
Price / Book Value ratio x9.36.4 146.0%  
Dividend payout %28.68.0 356.3%   
Avg Mkt Cap Rs m103,296272,778 37.9%   
No. of employees `0003.010.0 29.5%   
Total wages/salary Rs m3,37013,782 24.5%   
Avg. sales/employee Rs Th8,891.87,614.9 116.8%   
Avg. wages/employee Rs Th1,140.01,374.8 82.9%   
Avg. net profit/employee Rs Th878.3700.2 125.4%   
INCOME DATA
Net Sales Rs m26,28476,340 34.4%  
Other income Rs m504356 141.6%   
Total revenues Rs m26,78976,696 34.9%   
Gross profit Rs m3,66514,172 25.9%  
Depreciation Rs m1442,691 5.4%   
Interest Rs m81,789 0.5%   
Profit before tax Rs m4,01710,048 40.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4213,028 46.9%   
Profit after tax Rs m2,5967,019 37.0%  
Gross profit margin %13.918.6 75.1%  
Effective tax rate %35.430.1 117.4%   
Net profit margin %9.99.2 107.4%  
BALANCE SHEET DATA
Current assets Rs m14,44659,096 24.4%   
Current liabilities Rs m4,72540,018 11.8%   
Net working cap to sales %37.025.0 148.0%  
Current ratio x3.11.5 207.0%  
Inventory Days Days5175 68.6%  
Debtors Days Days20119 16.4%  
Net fixed assets Rs m1,11339,075 2.8%   
Share capital Rs m213282 75.3%   
"Free" reserves Rs m10,80830,281 35.7%   
Net worth Rs m11,07642,703 25.9%   
Long term debt Rs m024,873 0.0%   
Total assets Rs m16,241111,026 14.6%  
Interest coverage x497.06.6 7,510.9%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.60.7 235.4%   
Return on assets %16.07.9 202.1%  
Return on equity %23.416.4 142.6%  
Return on capital %36.317.5 207.5%  
Exports to sales %0.643.3 1.4%   
Imports to sales %12.67.4 170.1%   
Exports (fob) Rs m16233,044 0.5%   
Imports (cif) Rs m3,3225,672 58.6%   
Fx inflow Rs m26836,945 0.7%   
Fx outflow Rs m3,92761,066 6.4%   
Net fx Rs m-3,659-24,122 15.2%   
CASH FLOW
From Operations Rs m2,5143,449 72.9%  
From Investments Rs m-800-8,802 9.1%  
From Financial Activity Rs m-8036,986 -11.5%  
Net Cashflow Rs m912934 97.7%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 6.9 114.5%  
FIIs % 0.1 34.4 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 10.5 162.9%  
Shareholders   18,270 56,727 32.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   NOVARTIS  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Aug 21, 2017 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - NOVARTIS COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS